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Introduction. The International Circumpolar Surveillance network is a population-based surveillance system
that collects data on invasive pneumococcal disease (IPD) in Northern Canada. A 7-valent pneumococcal
conjugate vaccine was first introduced in some regions of Northern Canada in 2002, followed by 10-valent
(2009) and 13-valent (PCV-13) vaccines (2010). A 23-valent polysaccharide (PPV-23) vaccine was first
introduced in 1988 for special populations and adults aged 65 years and older. To describe the epidemiology
in the context of pneumococcal vaccination programs, we analysed surveillance data from Northern Canada
from 1999 to 2010.
Methods. A standardized case report form capturing demographic and clinical information was completed
for all IPD cases in Northern Canada meeting the national case definition. Isolates were sent to a reference
laboratory for confirmation, serotyping and antimicrobial resistance testing. Both laboratory and
epidemiological data were sent to the Public Health Agency of Canada for analysis. Population denominators
were obtained from Statistics Canada.
Results. From 1999 to 2010, 433 IPD cases were reported (average 36 cases per year). Incidence was greatest
among infants aged B2 years and among those aged 65 years and older, with an average annual incidence of
133 and 67 cases per 100,000 population, respectively. After a peak in incidence in 2008, rates among infants
have declined. Incidence rates varied from 2 to 16 times greater, depending on the year, among Aboriginals
compared to non-Aboriginals. Hospitalization was reported in 89% of all cases and the case fatality ratio was
6.0%. Clinical manifestations varied, with some patients reporting  1 manifestation. Pneumonia was the
most common (70%), followed by bacteremia/septicaemia (30%) and meningitis (8%). Approximately, 42% of
cases aged B2 years in 2009 and 2010 had serotypes covered by the PCV-13. In addition, the majority (89%)
of serotypes isolated in cases aged 65 years and older were included in the PPV-23 vaccine.
Conclusion. IPD continues to be a major cause of disease in Northern Canadian populations, with parti-
cularly high rates among infants and Aboriginals. Continued surveillance is needed to determine the impact
of conjugate pneumococcal vaccine programs. Additional studies investigating factors that predispose infants
and Aboriginal peoples would also be beneficial.
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T
he International Circumpolar Surveillance (ICS)
network was created in 1999 to establish a sur-
veillance network throughout Arctic countries
that would provide a means of assessing, monitoring
and analysing population-based rates of infectious dis-
eases for public health action (1). In 2000, it was adopted
as an Arctic Council Sustainable Development Working
Group Project, which promotes coordination and co-
operation among Arctic nations. Canada is an active
member in this surveillance network and has 6 partici-
pating regions, including the Northwest Territories,
Yukon, Nunavut, the Que ´bec Cree and Nunavik regions
and Northern Labrador. The ICS region is distinct from
the rest of Canada in its demography, with 57% of the
population self-declared as Aboriginal (First Nation,
Me ´tis or Inuit) compared to 4% in Canada overall. In
2011, the ICS population was estimated to be about
149,475 people, approximately 0.4% of the Canadian
population. Over the years, the scope of diseases in-
vestigated by this system has expanded; beginning with
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pneumoniae in 1999 to now include other bacterial infec-
tious agents such as Neisseria meningitidis and Heli-
cobacter pylori.
Invasive pneumococcal disease (IPD) is caused by the
Gram-positive bacteria S. pneumoniae. Invasive disease
may present with a variety of manifestations, which are
dependent on the site of infection, and may include
meningitis, bacteremia and pneumonia (2). Previous
research studies have indicated that incidence rates are
elevated among Aboriginal children as compared to non-
Aboriginal children (3,4). Ninety-two serotypes have
been identified globally, of which 15 cause the majority
of diseases.
In Canada, 4 pneumococcal vaccines have been
licensed and introduced. Between July 2002 and January
2007, the 7-valent pneumococcal conjugate vaccine
(PCV-7) was introduced into childhood immunization
schedules in Northern Canadian regions. This was
followed by the 10-valent pneumococcal conjugate vac-
cine (PCV-10), which was introduced between June 2009
and February 2010. Finally, the 13-valent pneumococcal
conjugate vaccine (PCV-13) was introduced between July
2010 and January 2011. All 3 vaccines were introduced as
provinces and territories adopted them into their routine
immunization programs. Serotypes covered in PCV-7
include 4, 6B, 9V, 14, 18C, 19F and 23F. PCV-10 covers
those in PCV-7 as well as an additional 3 serotypes (1, 5
and 7F). PCV-13 covers all serotypes in PCV-10 and
also includes serotypes 3, 6A and 19A.The schedule
recommended by the National Advisory Committee for
Immunization for all 3 conjugate vaccines has been con-
sistent, with a primary series of 3 doses given at 2, 4 and 6
months and a booster at 1218 months. The 23-valent
pneumococcal polysaccharide vaccine (PPV-23) is used
for targeted populations such as seniors and high-risk
groups (5). Serotypes covered by PPV-23 include 1, 2, 3,
4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C,
19A, 19F, 20, 22F, 23F and 33F.
Given that S. pneumoniae is a leading cause of pneu-
monia and meningitis in the circumpolar north among
Aboriginal persons, and that changes in the epidemiology
have been observed in other Arctic countries pre- and
post-PCV-7 implementation (6), continued surveillance of
this invasive disease is important. Therefore, the objective
of this study was to describe the epidemiology of IPD in
the context of pneumococcal vaccination programs in
Northern Canada from 1999 to 2010.
Methods
Using the ICS network of public health personnel and
laboratories, all cases of IPD with S. pneumoniae isolated
from a normally sterile site (excluding the middle ear and
pleural cavity) who resided in any of the 6 participating
regions from 1999 to 2010 were identified and included in
this study. For a detailed description of the ICS network,
see Ref. 1.
Isolates from confirmed cases were sent to one of
3 references laboratories: the National Centre for
Streptococcus, the National Microbiology Laboratory
(NML), or the Laboratoire de sante ´ publique du Quebec
(LSPQ) for serotyping and antimicrobial susceptibility
testing. Serotyping was performed using the Quellung
reaction using pool, group, type and factor commercial
antisera from SSI Diagnostica; Statens Serum Institute,
Copenhagen, Denmark. All 3 laboratories participate
in on-going quality control testing. Antimicrobial sus-
ceptibilities to cefotaxime, ceftriaxone, chloramphenicol,
clindamycin, erythromycin, levofloxacin, penicillin, tetra-
cycline, trimethoprim/sulfamethoxazole, vancomycin were
determined by microbroth dilution (Sensititire STP6F,
Thermo Fisher Scientific, Ottawa, ON) in accordance
with the Clinical and Laboratory Standards Institute
(CLSI) guidelines (7,8).
Epidemiological information was collected by a com-
municable disease officer in participating regions using a
standardized case report form, which includes data such
as demographic information, self-identified Aboriginal
status, risk factors for disease (e.g. asthma, smoking),
relevant immunization information, outcome and clinical
manifestations. Both the laboratory and epidemiological
data was forwarded to the Center for Immunization
and Respiratory Infectious Diseases (CIRID) at the
Public Health Agency of Canada (PHAC) for data entry,
cleaning, collation and analysis. Laboratory and epide-
miological data were entered into an Access database and
verified by each participating region during annual data
audits.
Population estimates were obtained using Statistics
Canada’s annual census subdivision and territorial July
1st estimates. These estimates were obtained on an annual
basis. Aboriginal population estimates were developed for
each year using data from the 2006 Canadian Census.
Excel 2010 and SAS version 9.1 were used for the analysis.
Results
From 1999 to 2010, a total of 433 IPD caseswere reported
through the ICS system in Northern Canada (average of
36 cases per year). Figure1 depicts the numberof reported
cases and incidence rates throughout this surveillance
period. The average annual incidence was 25.8 cases
per 100,000 population; however, the number of cases
and incidence rates fluctuated, from a low of 23 (16.2 per
100,000 population) in 2005 to a high of 51 (37.9 per
100,000) in 2001.
As presented in Fig. 2, incidence varied by age group
with the highest average annual incidence rate occur-
ring in infants agedB2 years (132.8 cases per 100,000
population). Incidence rates among infants agedB2 years
showed a steady decline from 1999 to 2004 when they
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this, incidence began to climb to a high of 224.1 cases per
100,000 population in 2008. Since then, rates have sharply
declined to 26.5 cases per 100,000 population in 2010.
On average, infants aged B2 years made up 19% of all
IPD cases from 1999 to 2010.
The age group with the second greatest burden of
illness was those aged 65 years and older, with an average
annual incidence rate of 66.9 cases per 100,000 popula-
tion. The incident rate decreased from 2001 to 2006 but
has been on the rise since then. On average, adults aged
65 years and older comprised 13% of IPD cases eachyear.
Cases in the 219 and 2064 age groups had an average
annual incidence of 15.4 and 20.2 cases per 100,000
population, respectively. Rates for these two age groups
have been relatively stable over the years.
From 1999 to 2010, 75% of cases occurred in self-
identified Aboriginals, 14% occurred in non-Aboriginals
and 11% had an unknown ethnicity. Table 1 presents the
incident rates by ethnicity for each year. The average
annual incidence rate among Aboriginals was 33.7 cases
per 100,000 population and was higher compared to the
averageincidencerateof8.5casesper100,000amongnon-
Aboriginals throughout the surveillance period. Rates
among Aboriginal cases fluctuated from a low of 18.3
cases per 100,000 population in 2005 to a high of 57.6
cases per 100,000 population in 2001. In each year, rates
among Aboriginals were greater than non-Aboriginals
and depending on the year, ranged from 2 to 16 times
higher.
Clinical manifestation of cases varied with some re-
porting more than one manifestation. Pneumonia was
Fig. 2. Incidence rate (per 100,000 population) of invasive pneumococcal disease in Northern Canada by age group and year,
19992010.
Fig. 1. Reported cases and incidence rate (per 100,000 population) of invasive pneumococcal disease in Northern Canada by year,
19992010.
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septicaemia (30%), meningitis (8%), empyema (3%) and
septic arthritis and cellulitis reported in 1% of cases.
Severity of illness was assessed using hospitalization
and mortality information. A total of 366 cases were
hospitalized throughout the surveillance period, repre-
senting 89% of cases with hospitalization data. In addi-
tion, 26 deaths were reported, resulting in an average
annual case fatality ratio of 6%. The ratio fluctuated from
no deaths reported in 2000 and 2003 to a high of 15.2% in
2009. The highest overall case fatality ratio of 20% was
reported in cases aged 60 years and older, followed by 6%
in cases aged 2064 years of age. The overall case fatality
ratio among cases aged B2 years of was 4% and no
deaths were reported among cases between 2 and 19 years
of age. There was no association observed between sero-
type and outcome.
Antibiotic susceptibility testing was carried out on
94100% of isolates, depending on the antibiotic tested.
The majority of isolates were susceptible to penicillin,
ceftriaxone, vancomycin, clindaymycin, erythromycin,
trimethoprim/sulfamethoxazole and choloramphenicol;
however, some isolates did show intermediate or full
resistance to trimethoprim/sulfamethoxazole (9%), ery-
thromycin (6%), penicillin (5%), ceftriaxone (2%) and
clindamycin (2%).
The distribution of serotypes by conjugate vaccine
category from 1999 to 2010 is presented in Fig. 3. The
proportion of cases that occurred as a result of a sero-
type included in PCV-7 (4, 6B, 9V, 14, 18C, 19F, 23F)
decreased throughout the early 2000s to a low of 6% in
2004, after which it increased to 37% of cases in 2006.
Since then, it has decreased, with only 7% of cases due to
PCV-7 in 2010. The proportion of cases with one of the
3 serotypes covered by PCV-10 but not PCV-13 (1, 5, 7F)
has decreased during the study period, from a high of
43% in 2001 to 0% in 2006. These serotypes accounted for
13% of cases in 2010. The proportion of cases with a
serotype covered by PCV-13 but not PCV-10 (3, 6A, 19A)
was greatest in 2005 (22%) but has decreased slightly
(17%) since 2010.
Overall, 37% of cases had a serotype covered by one of
the 13 serotypes contained in PCV-13 in 2010. Similarly,
on average 42% of cases among infants agedB2 years
had a serotype covered by PCV-13 from 2009 to 2010.
The proportion of cases in all age groups with sero-
types not included in the vaccine ranged from 13 to
20% from 1999 to 2002; since 2008,  50% of cases had
serotypes not included in the vaccine. The most common
serotypes from 2007 to 2010 were 8, 7F and 19A, making
up 14, 8 and 7% of cases with known serotypes,
respectively.
Among those aged 65 years of age and older, from
1999 to 2006 an average of 93% of cases had serotypes
that were included in PCV-13; however, in 2008 and 2009
only 23% had a PCV-13 serotype. From 1999 to 2010, an
average of 89% of cases aged 65 years and older had a
serotype covered by PPV-23 (i.e. serotypes 1, 2, 3, 4, 5,
6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A,
19F, 20, 22F, 23F and 33F) each year. Of the cases with a
serotype included in PPV-23, 63% had received at least
one dose of the vaccine 121 years prior to symptom
onset, 25% had not been previously vaccinated with PPV-
23, and 12% had an unknown vaccination history.
Discussion
Within Canada, there are a limited number of surveil-
lance systems that capture both laboratory and epide-
miological information on vaccine preventable diseases.
The ICS system continues to be an excellent example of
this partnership and is fundamental to the understanding
of the changing epidemiology of IPD in the Arctic. The
ICS system has demonstrated that IPD continues to be
an important cause of morbidity in Northern Canada.
Incident rates in the North were 1.54.5 times greater
than national rates, depending on the year, through-
out this surveillance period (9). Infants, adults aged
65 years and older, and Aboriginals are particularly
affected.
Within the study period, the Aboriginal population
was disproportionately affected each year, with rates
216 times greater than those of non-Aboriginal persons.
These findings correspond with other research studies
that have identified a greater burden of IPD in Aboriginal
populations (6,10,11). Several studies have cited multiple
possible risk factors such as crowded living conditions,
socio-economic status, underlying medical conditions and
a greater exposure to risks such as smoking (6,10,11) as
possible explanations.
Throughout this surveillance period, the greatest
burden of illness was observed in young infants followed
Table 1. Incidence rate (per 100,000 population) of invasive
pneumococcal disease in Northern Canada by ethnicity and
year, 19992010
Year Aboriginal Non-Aboriginal Unknown Total
1999 41.1 3.6 0.0 25.6
2000 41.1 18.0 2.2 33.7
2001 57.5 3.6 3.0 37.9
2002 31.6 10.5 2.9 25.7
2003 23.7 8.6 4.3 21.7
2004 29.5 10.1 2.8 24.2
2005 18.3 8.3 2.1 16.2
2006 23.0 8.2 2.1 18.8
2007 38.5 13.0 3.5 31.1
2008 28.7 6.4 3.4 22.6
2009 40.3 8.0 4.8 31.3
2010 31.7 3.1 0.7 20.1
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greatest burden of illness in Canadian data, rates within
the ICS population surpassed national rates. In children
aged B1 year, the difference in the ICS region was 413
times greater in the period 20052010 (9).
Vaccine coverage assessments in the Canadian North
continue to be a challenge, resulting in difficulties
determining the potential role of inadequate coverage
(12). Current national survey methodologies have several
limitations, including the use of random digit dialling
(thus excluding households without a telephone), relying
on parental recall (therefore potentially underestimating
coverage) and a sample size within the Canadian North
that is too small to allow for provincial coverage
estimates (12). The lack of information on coverage
results in difficulties assessing the role of under-immuni-
zation in IPD incidence in the Canadian North and
warrants further research.
Since 1999, the number of IPD cases caused by a
serotype covered by a pneumococcal conjugate vaccine
has decreased. At the same time, there has been an in-
crease in cases with serotypes not covered by a conjugate
vaccine. At this time, it is unclear whether this change is
due to serotype replacement versus natural fluctuations
in circulating strains. For cases aged 65 years and older,
the majority of disease was due to serotypes covered
by the PPV-23 vaccine. It should be noted that PCV-13
has been licensed for use in adults in Canada, and the
National Advisory Committee on Immunization is cur-
rently reviewing the evidence for its use in this popula-
tion. Further research on the uptake of pneumococcal
vaccines and waning immunity in adults aged 65 years
and older should be conducted.
Limitations
The Canadian ICS region represents only 0.4% of the
Canadian population and is located in the Arctic North;
therefore, the generalizability of this analysis may not be
applicable to other parts of Canada and other industria-
lized countries. The small number of cases and small
population sizes need to be taken into consideration when
interpreting results, as even one case can cause great
variation from year-to-year incidence rates. Data on risk
factors may not have been adequately captured, thereby
limiting our understanding of predisposing factors for
infection. In addition, not all cases had complete hospi-
talization and death data, which may underestimate the
severity of illness observed during this study period. It is
unknown whether antibiotics were administered prior to
specimen collection, which may result in anunderestimate
of the true number of cases. Finally, information captured
on vaccination history was insufficient to determine if
vaccination failures occurred.
Conclusions
IPD is an important infection that causes significant
morbidity and mortality in the Canadian North, espe-
cially in high-risk populations, such as infants, the elderly
and Aboriginal persons. Further analysis regarding the
impact of conjugate pneumococcal vaccines in reducing
IPD incidence in the Canadian ICS region is needed.
On-going surveillance will provide necessary information
regarding IPD epidemiology, circulating serotypes, the
Fig. 3. Reported cases of invasive pneumococcal disease by serotype category* in Northern Canada by year, 19992010.
*PCV-7 serotype encompasses cases with serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F. PCV-10 serotype encompasses cases with serotypes
included in PCV-10 but not PCV-7 (i.e. serotypes 1, 5, and 7F). PCV-13 serotype encompasses cases with serotypes included in PCV-13
but not PCV-10 (i.e. serotypes 3, 6A, and 19A). Other serotype encompasses cases with serotypes not included in any conjugate vaccine
formulation.
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studies investigating factors that predispose infants and
Aboriginal peopleswould also be beneficial. On-going use
of the PPV-23 vaccine among the elderly is recommended
as are immunization coverage surveys in the North.
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